'BioConversations'
Only company from the global biotech industry to be recognized as ‘industry mover’ Biocon (including Biocon Biologics) is proud to be recognized as the “Industry Mover” in the S&P Global Sustainability Yearbook 2023. Biocon is the only company to be named as “Industry Mover” this year from the Biotechnology industry. Biocon is also the only Biotechnology company from … Continue reading Biocon Recognized Among World’s Most Sustainable Companies in S&P Global 2023 Sustainability Yearbook
The world is just emerging from the economic impact of the COVID-19 pandemic. The people who suffered the economic fallout of the pandemic as their incomes shrunk, urgently need of access to cheaper drugs. This has been the case not only in the emerging markets, but also in the developed countries. Generics and biosimilars which … Continue reading Biocon Biologics Reports a Healthy Business Performance in July-September Quarter
The global economy is in its steepest slowdown since 1970. The IMF has forecast that global economic growth will slow to 3.2% in 2022 and 2.9% in 2023 from 6.1% in 2021. While high inflation continues to make headlines across the globe, spiralling healthcare costs need to be addressed. Biosimilars, which provide affordable access to … Continue reading Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
Tricolor Distributed Among Children of govt schools, to Communities and Biocon Group’s staff amidst the singing of the National Anthem and National Song The Biocon Group participated in the Diamond Jubilee (75 years) celebrations of India’s Freedom over three days. The Har Ghar Tiranga campaign, initiated by the Government of India, had a good response; the Biocon Group of companies came together to distribute 30,000 flags among schoolchildren, their parents, general public and Biocon’s employees.
Biocon's Chairperson Kiran Mazumdar-Shaw in a QnA with FE’s Srinath Srinivasan, talks about the bold moves Biocon Biologics is making since 2021, including the recent acquisition of Viatris’ global biosimilars business, which will provide it a direct entry into the US & Europe with the acquired commercial engine in developed and key emerging markets. This … Continue reading Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
India's premier biopharmaceutical company Biocon is working on a pipeline of 20 biosimilar drugs or similar but not identical copy of biologic medicines, to tap the upcoming huge opportunity. Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products. It has biosimilars in oncology like … Continue reading Biocon developing 20 biosimilar products for global markets
By Dr. Viraj Suvarna Is there a real issue about access to diabetes care? Sir Francis Peabody, renowned physician, says, that the secret in the caring of the patient is in caring for the patient. In other words, despite a plethora of options, Indian patients with diabetes still do not have access to comprehensive diabetes … Continue reading Access to diabetes care; if not now, when?
If you are concerned about your breast health, you might be wondering if there are ways to lower the risk of breast cancer? While one cannot do much about a few risk factors such as being a female or getting older, it is still possible to reduce the risk by adopting some healthy lifestyle habits. … Continue reading HOW CAN I REDUCE MY RISK OF BREAST CANCER?
Dr Arun Chandavarkar, Managing Director, Biocon Biologics Ltd., says the structure of the strategic alliance with Serum Institute Life Sciences provides Biocon Biologics with an asset light and accelerated entry into the often overlooked infectious diseases segment. Having established capabilities and a track record of success in biologics, Biocon Biologics’ foray into vaccines and antibodies for … Continue reading ‘Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines’
A Blog by Biocon 